Clinical trials: CVC
Healthy
Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination
This is a Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole and Famotidine, on the PK of CVC
- Trial name
- NCT02684799
- Testing
- Cenicriviroc, Omeprazole, Famotidine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Tobira Therapeutics, Inc.
Surgery, Central Line Associated Blood Stream Infections (CLABSI)
BIP CVC Clinical Safety and Performance Study
The primary objective of this trial was to determine Bactiguard coated BIP CVC's safety and performance and compare it to corresponding standard uncoated CVC.
- Trial name
- NCT02811380
- Testing
- BIP CVC, Uncoated Standard CVC
- Where
- Sweden
- Volunteers
- 36 people
- Sponsor
- Bactiguard AB
Healthy
Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination
A single center, open-label, fixed sequence study to evaluate the pharmacokinetics (PK) of Cenicriviroc (CVC) administered with and without Pioglitazone (PGZ), and to evaluate the PK of PGZ administered with and without CVC.
- Trial name
- NCT02342067
- Testing
- Cenicriviroc, Pioglitazone
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tobira Therapeutics, Inc.
Healthy
Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin
This is a Phase 1, Open-Label, 3-Period, Single-sequence, Drug-drug Interaction Study in Healthy Subjects to Assess the Effect of Cenicriviroc on the Pharmacokinetics (PK) of HMG-CoA Reductase Inhibitors [Rosuvastatin (ROS)…
- Trial name
- NCT02685462
- Testing
- Rosuvastatin, Atorvastatin, Simvastatin
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Tobira Therapeutics, Inc.
HIV-1 Infection
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
This is a randomized, double-blind, double-dummy, 48-week, comparative study. Approximately 150 HIV-infected, treatment-naïve patients with CCR5-tropic virus will be stratified by HIV-1 RNA: ≥100,000 copies/mL versus <100,000…
- Trial name
- NCT01338883
- Testing
- Cenicriviroc 100 mg, Cenicriviroc 200 mg + Truvada, Sustiva + Truvada
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 143 people
- Sponsor
- Tobira Therapeutics, Inc.
Bacteriaemia, Catheter Related Bloodstream Infection
Rate of Catheter Colonization and Risk of Bloodstream Infection During Use of Two Different Central Venous Catheters (CVC)
The use of these catheters is associated with infectious complications that are an important iatrogenic source of morbidity and mortality.
- Trial name
- NCT00555282
- Testing
- central venous catheter
- Where
- 2 sites in Czechia
- Volunteers
- 680 people
- Sponsor
- B. Braun Melsungen AG
Dialysis Catheter Infections
Efficacy Study to Evaluate B-Lock™ as an Antimicrobial Lock Solution in Dialysis Patients With a CVC
Hypothesis: B-Lock is a safe and effective catheter lock solution that will maintain catheter patency and reduce Central Line Associated Blood Stream Infections (CLABSI) in dialysis patients using a central venous catheter (CVC)…
- Trial name
- NCT01989091
- Testing
- B-Lock, Heparin 5,000 U/mL
- Where
- 21 sites in Hungary, Poland
- Volunteers
- 270 people
- Sponsor
- Great Lakes Pharmaceuticals Inc.
Liver Insufficiency
Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment
To determine whether CVC exposures are altered in subjects with impaired hepatic function, compared to subjects with normal hepatic function.
- Trial name
- NCT02120547
- Testing
- Cenicriviroc in mild liver impaired, Cenicriviroc in moderate liver impaired
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Tobira Therapeutics, Inc.
Catheter-Associated Infections, Catheter-Related Infections
Safety and Effectiveness of Novel Nitroglycerin Based Catheter Lock Solution
The objective of this Phase I/II pilot study is to evaluate the safety and effectiveness of a non- antibiotic chelator based lock solution that contains nitroglycerin in combination with sodium citrate and ethanol (NiCE lock…
- Trial name
- NCT02577718
- Testing
- Nitroglycerin-citrate-ethanol (NiCE)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novel Anti-Infective Technologies, LLC
Sepsis, Bacteremia
Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections
Central venous catheters (CVCs) are used in patient care for such purposes as the administration of medication, fluids, blood products and for functions such as hemodialysis and plasmapheresis.
- Conditions
- Sepsis, Bacteremia, Fungemia
- Trial name
- NCT00027248
- Testing
- MBI 226
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- BioWest Therapeutics Inc
RRMM
A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients
This is a randomized, two-period, cross-over Phase 2 study, comparing PK, and assessing safety and tolerability and efficacy of peripheral and central intravenous administration of melflufen in patients with RRMM.
- Trial name
- PORT (NCT04412707)
- Testing
- Melphalan, Dexamethasone
- Where
- 10 sites in United States, Bulgaria and 3 more
- Volunteers
- 27 people
- Sponsor
- Oncopeptides AB
HIV-infection/AIDS
Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam
To evaluate the PK, safety and tolerability of Cenicriviroc (CVC) administered with and without Dolutegravir (DTG) and CVC with and without a single dose of Midazolam in healthy subjects.
- Trial name
- NCT01827540
- Testing
- Cenicriviroc, Dolutegravir, Midazolam
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tobira Therapeutics, Inc.
Nonalcoholic Steatohepatitis
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)
The AURORA study will be conducted to confirm the efficacy and safety of cenicriviroc (CVC) for the treatment of liver fibrosis in adult participants with NASH.
- Trial name
- AURORA (NCT03028740)
- Testing
- Cenicriviroc
- Where
- 346 sites in United States, Australia and 26 more
- Volunteers
- 1,778 people
- Sponsor
- Tobira Therapeutics, Inc.
Central Line Associated Blood Stream Infections (CLABSI)
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult and adolescent participants receiving home Total Parenteral Nutrition (TPN)…
- Trial name
- NCT06822426
- Testing
- (taurolidine and heparin) catheter lock solution, Heparin
- Where
- 24 sites in United States, Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- CorMedix Therapeutics
Non-alcoholic Steatohepatitis (NASH)
Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis
The purpose of this study was to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis.
- Trial name
- TANDEM (NCT03517540)
- Testing
- Tropifexor (LJN452), Cenicriviroc (CVC)
- Where
- 65 sites in United States, Argentina and 15 more
- Volunteers
- 193 people
- Sponsor
- Novartis Pharmaceuticals
Bacterial Infections
Safety and Efficacy Study of Angiotech Central Venous Catheter to Prevent Bacterial Catheter Colonization
The main purpose of this study is to determine if the Angiotech central venous catheter (CVC) is equal in effectiveness to a CVC coated with chlorhexidine and silver sulfadiazine in preventing bacterial catheter colonization.
- Trial name
- NCT00288418
- Testing
- Central Venous Catheter
- Where
- 21 sites in United States
- Volunteers
- 960 people
- Sponsor
- Angiotech Pharmaceuticals
Vascular Access Complication, Catheter-Related Infections
BIP CVC in Access Center at Danderyd Hospital, Stockholm, Sweden
Primary objective of the study is to establish the incidence of all any catheter related complications in BIP CVC and standard CVC groups in patients requiring CVC.
- Conditions
- Vascular Access Complication, Catheter-Related Infections, Catheter Thrombosis, Catheter Blockage
- Trial name
- IMPROWE (NCT03976557)
- Testing
- BIP CVC, Standard CVC
- Where
- Sweden
- Volunteers
- 19 people
- Sponsor
- Bactiguard AB